Hospitals and other covered entities participating in the 340B Drug Pricing Program may be eligible for a refund for drugs purchased from Genentech. The pharmaceutical company recently recalculated the 340B ceiling prices for 25 products for the third quarter of 2012 through the second quarter of 2013.

Genentech will issue refunds to covered entities when data shows a difference between the price paid and the recalculated 340B ceiling price for direct and indirect purchases of affected products. Covered entities must contact Genentech no later than Dec. 31 to receive a refund.

Genentech previously issued refunds for similar 340B drug overcharges in 2013. The pharmaceutical company overcharged covered entities from 2008 through 2011 for oncology medicines widely used to treat non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and cancers of the brain, breast, colon, lung, and kidney.

Contact Erin O’Malley, director of policy, at eomalley@essentialhospitals.org or 202.585.0127 with any questions.